Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Diamondcutter who wrote (3811)	5/2/1998 4:04:00 PM
From: Michael	Read Replies (1) \| Respond to of 7041

My Friend Diamondcutter: I do not know anything about you. I am not calling you a shill. I might have thrown out a baited hook on this thread, and look what I caught. Your Friend, Michael

To: Diamondcutter who wrote (3811)	5/2/1998 9:29:00 PM
From: Linda Kaplan	Respond to of 7041

You're right that people often invest on the basis of future earnings. In my opinion, Zona's chances of good future earnings are slim. I can understand that others think differently, especially in view of the hype that the CEO has been spreading around about the potential of Vasomax. Take a look at the figures in the poster, though. Do they jive with what he's been saying to the press, not to mention inspire confidence in the efficacy of the drug? They start with a population of people with minimal problems. How is that defined? What happened to the numerous drop outs from the studies? Various press releases provide details on large numbers of disappeared people from the studies, even after they eliminated people with serious side effects, and only took people with minimal (whatever that is) problems in the first place. There are a lot of reasons to think this drug doesn't work at all and that if it does, only on the same population that Viagra serves, but not as well as Viagra. So, where would the future earnings come from? Linda